CNTA
Centessa Pharmaceuticals PLC ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website centessa.com
- Employees(FY) 75
- ISIN US1523091007
Performance
+2.52%
1W
+0.06%
1M
+57.8%
3M
+67.79%
6M
+99.62%
YTD
+125.39%
1Y
Profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Technical Analysis of CNTA 2024-11-04
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-04 07:30
- 2024-11-03 18:30
- 2024-10-23 17:36
- 2024-10-12 10:18
- 2024-10-09 08:04
- 2024-09-26 06:00
- 2024-09-25 18:00
- 2024-09-20 14:49
- 2024-09-20 05:39
- 2024-09-19 07:38
- 2024-09-19 05:50
B. Riley Initiates Centessa Pharmaceuticals at Buy(MT Newswires)
- 2024-09-13 09:11
- 2024-09-13 08:52
Sector Update: Health Care(MT Newswires)
- 2024-09-13 05:50
- 2024-09-13 03:25
- 2024-09-12 22:34
- 2024-09-12 10:34
- 2024-09-11 17:07
- 2024-09-11 16:04
- 2024-09-11 04:04
- 2024-09-10 16:34
Centessa Reverses Lower Despite $5 Billion Narcolepsy Opportunity(Investor's Business Daily)
- 2024-09-10 14:09
Top Midday Gainers(MT Newswires)
- 2024-09-10 14:08
- 2024-09-10 13:42
Sector Update: Health Care(MT Newswires)
- 2024-09-10 13:03
- 2024-09-10 12:19
- 2024-09-10 08:15
Investors are waking up to Centessa’s sleepiness drug(BioPharma Dive)
- 2024-09-10 07:00
- 2024-09-09 23:18
- 2024-09-09 19:00
Page 1 of 6
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.